The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.
暂无分享,去创建一个
Donna Neuberg | Steven M Kornblau | Johannes Köster | David A. Williams | Paul van Hummelen | Henry W. Long | David P Steensma | David M Weinstock | Benjamin L Ebert | David M Dorfman | Andrew P Weng | Raphael Koch | Zachary T Herbert | Kimberly Stegmaier | Shai Izraeli | Emma Lees | Marina Konopleva | Jerome Ritz | Rachel R. Paquette | Irmela Jeremias | David A Williams | Hui Gao | Andrew L Kung | Myles Brown | P. van Hummelen | A. Letai | A. LaCasce | D. Neuberg | A. Look | S. Orkin | J. Aster | M. Shipp | Myles A Brown | B. Ebert | M. Bertagnolli | K. Stegmaier | A. Weng | S. Sallan | Elizabeth C. Townsend | A. Thorner | M. Harris | L. Silverman | I. Jeremias | J. Ritz | M. Konopleva | M. Andreeff | R. Clark | T. Graubert | Hui Gao | M. Wiesmann | E. Lees | A. Lane | A. Freedman | G. Inghirami | J. Griffin | D. Dorfman | Mark A. Murakami | A. Christodoulou | A. Christie | J. Köster | Tiffany DeSouza | E. Morgan | Scott Kallgren | Huiyun Liu | Shuo-chieh Wu | Olivia Plana | J. Montero | K. Stevenson | P. Rao | Raga Vadhi | P. Armand | K. Ballen | Patrizia Barzaghi-Rinaudo | Sarah Cahill | Vesselina G. Cooke | M. Davids | D. DeAngelo | Hilary Eaton | J. Etchin | B. Firestone | D. Fisher | I. Galinsky | Jacqueline S. Garcia | F. Garnache-Ottou | A. Gutierrez | Ensar Halilovic | S. Horwitz | A. Intlekofer | Moriko Ito | S. Izraeli | E. Jacobsen | C. Jacobson | S. Jeay | M. Kelliher | R. Koch | N. Kopp | S. Kornblau | A. Kung | T. Kupper | N. LeBoeuf | Loretta S. Li | M. Murakami | M. Muschen | S. Ng | O. Odejide | A. Place | J. Roderick | J. Ryan | B. Shoji | R. Soiffer | D. Steensma | R. Stone | J. Tamburini | M. Wadleigh | J. Wuerthner | Bruce Wollison | D. Weinstock | P. Hummelen | Michael Andreeff | Michelle A Kelliher | Giorgio Inghirami | Francine Garnache-Ottou | Stuart H Orkin | Jon C Aster | Thomas S Kupper | M. Müschen | Marion Wiesmann | James D Griffin | Richard M Stone | Daniel J DeAngelo | Timothy A Graubert | Margaret A Shipp | Elizabeth C Townsend | Mark A Murakami | Alexandra Christodoulou | Amanda L Christie | Tiffany A DeSouza | Elizabeth A Morgan | Scott P Kallgren | Huiyun Liu | Shuo-Chieh Wu | Olivia Plana | Joan Montero | Kristen E Stevenson | Prakash Rao | Raga Vadhi | Philippe Armand | Karen K Ballen | Patrizia Barzaghi-Rinaudo | Sarah Cahill | Rachael A Clark | Vesselina G Cooke | Matthew S Davids | Hilary Eaton | Julia Etchin | Brant Firestone | David C Fisher | Arnold S Freedman | Ilene A Galinsky | Jacqueline S Garcia | Alejandro Gutierrez | Ensar Halilovic | Marian H Harris | Steven M Horwitz | Andrew M Intlekofer | Moriko Ito | Eric D Jacobsen | Caron A Jacobson | Sébastien Jeay | Nadja Kopp | Nicole R LeBoeuf | Ann S LaCasce | Loretta S Li | A Thomas Look | Masato Murakami | Markus Muschen | Samuel Y Ng | Oreofe O Odejide | Rachel R Paquette | Andrew E Place | Justine E Roderick | Jeremy A Ryan | Stephen E Sallan | Brent Shoji | Lewis B Silverman | Robert J Soiffer | Jerome Tamburini | Aaron R Thorner | Martha Wadleigh | Jens U Wuerthner | Bruce M Wollison | Andrew A Lane | Anthony Letai | Monica M Bertagnolli | Henry Long | Oreofe O. Odejide | Zachary T. Herbert | P. Van Hummelen | Nadja Kopp | Alejandro Gutiérrez | V. Cooke | H. Gao | Myles A. Brown | M. Ito | J. Garcia | Hui Gao | Olivia D Plana | J. Ryan | M. Ito | Alejandro Gutierrez | Moriko Ito | Johannes Köster
[1] M. Wiesmann,et al. Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097 , 2015, Molecular Cancer Therapeutics.
[2] P. Meltzer,et al. The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. , 2013, Cancer research.
[3] Christopher A. Miller,et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. , 2014, Cancer cell.
[4] Andrew L. Kung,et al. Examining the utility of patient-derived xenograft mouse models , 2015, Nature Reviews Cancer.
[5] J. Byrd,et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.
[6] Michael Becker,et al. Establishment of Patient-Derived Non–Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers , 2008, Clinical Cancer Research.
[7] Philippe Dessen,et al. Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer , 2012, Clinical Cancer Research.
[8] Sven Rahmann,et al. Snakemake--a scalable bioinformatics workflow engine. , 2012, Bioinformatics.
[9] Giovanni Parmigiani,et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. , 2009, Cancer research.
[10] Manuel Hidalgo,et al. Patient-derived xenograft models: an emerging platform for translational cancer research. , 2014, Cancer discovery.
[11] Anne Vincent-Salomon,et al. Molecular profiling of patient-derived breast cancer xenografts , 2012, Breast Cancer Research.
[12] Matthew E. Ritchie,et al. limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.
[13] John D. Storey,et al. Capturing Heterogeneity in Gene Expression Studies by Surrogate Variable Analysis , 2007, PLoS genetics.
[14] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[15] Eduardo Sontag,et al. Transcriptional control of human p53-regulated genes , 2008, Nature Reviews Molecular Cell Biology.
[16] K. Cibulskis,et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes , 2015, Nature Biotechnology.
[17] Pengcheng Lv,et al. Recent advances of p53-MDM2 small molecule inhibitors (2011-present). , 2015, Current medicinal chemistry.
[18] Hans Bitter,et al. A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097 , 2015, eLife.
[19] Eric Vangrevelinghe,et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition , 2011, The Journal of experimental medicine.
[20] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[21] Heidi Ledford,et al. Translational research: 4 ways to fix the clinical trial , 2011, Nature.
[22] Jean-Pierre Gillet,et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance , 2011, Proceedings of the National Academy of Sciences.
[23] Christopher J. Ott,et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. , 2012, Blood.
[24] Joshua M. Korn,et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.
[25] Chad A Shaw,et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. , 2013, Cancer research.
[26] R. Brenner,et al. Phenotypic instability of Saos-2 cells in long-term culture. , 2005, Biochemical and biophysical research communications.
[27] N. Harris,et al. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. , 2008, Blood.
[28] N. Harris,et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. , 2012, Blood.
[29] Davide Corà,et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.
[30] M. Konopleva,et al. Role of Microenvironment in Resistance to Therapy in AML , 2015, Current Hematologic Malignancy Reports.
[31] Thomas M. Keane,et al. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer , 2014, Nature.
[32] P. Vyas,et al. Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia , 2015, Clinical Cancer Research.
[33] R. Lock,et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. , 2004, Blood.
[34] Karen Cichowski,et al. Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy , 2015, Cell.
[35] M. Ghert,et al. Lost in translation: animal models and clinical trials in cancer treatment. , 2014, American journal of translational research.